Robert A. Heft
Direktor/Vorstandsmitglied bei CLEMENTIA PHARMACEUTICALS INC
Profil
Robert A.
Heft was the founder of IBEX Technologies, Inc. (founded in 1972) where he held the title of President, Director & Chief Scientist from 1972 to 2001.
He currently holds the position of Independent Director at Lumos Pharma Sub, Inc., Independent Director at Clementia Pharmaceuticals, Inc., and Director at Parvus Therapeutics, Inc. He previously held positions such as President, Chief Executive Officer & Director at Enobia Pharma, Inc. from 2010 to 2012, Chief Executive Officer & Director at Zingenix Ltd.
from 2014 to 2019, and Chairman at Eloxx Pharmaceuticals Ltd.
He has also served as a Director at VisionGate, Inc., Ra Pharmaceuticals, Inc., Biocapital Investments Ltd, Canadian Genetic Disease Network, and Industrial Biotechnology Association of Canada.
Additionally, he was Vice President-Product Development at BioMarin Pharmaceutical, Inc. from 2001 to 2004 and Executive-in-Residence at Sectoral Asset Management, Inc. He obtained his undergraduate degree from McGill University, a doctorate from Massachusetts Institute of Technology in 1986, and a graduate degree from Cornell University.
Aktive Positionen von Robert A. Heft
| Unternehmen | Position | Beginn |
|---|---|---|
| CLEMENTIA PHARMACEUTICALS INC | Direktor/Vorstandsmitglied | 01.06.2013 |
Lumos Pharma Sub, Inc.
 Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Direktor/Vorstandsmitglied | - |
Parvus Therapeutics, Inc.
 Parvus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Parvus Therapeutics, Inc. manufactures and sells biopharmaceutical products. The private company is based in Calgary, Canada. | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Robert A. Heft
| Unternehmen | Position | Ende |
|---|---|---|
| RA PHARMACEUTICALS, INC. | Direktor/Vorstandsmitglied | 02.04.2020 |
Zingenix Ltd.
 Zingenix Ltd. BiotechnologyHealth Technology Zingenix Ltd. provides gene therapy for orphan disorders. The private company is based in Tel Aviv, Israel. | Vorstandsvorsitzender | 01.03.2019 |
| ELOXX PHARMACEUTICALS, INC. | Vorsitzender | 27.12.2017 |
Enobia Pharma, Inc.
 Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Vorstandsvorsitzender | 01.02.2012 |
| BIOMARIN PHARMACEUTICAL INC. | Corporate Officer/Principal | 01.01.2004 |
Ausbildung von Robert A. Heft
| Cornell University | Graduate Degree |
| McGill University | Undergraduate Degree |
| Massachusetts Institute of Technology | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BIOMARIN PHARMACEUTICAL INC. | Health Technology |
| ELOXX PHARMACEUTICALS, INC. | Health Technology |
| Private Unternehmen | 13 |
|---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
IBEX Technologies, Inc.
 IBEX Technologies, Inc. Medical SpecialtiesHealth Technology IBEX Technologies, Inc. manufactures and markets enzymes for biomedical use. The firm also specializes in the custom aliquoting, filling, and lyophilization of enzymes in diagnostic disposables for medical devices. Its products include glycobiology enzymes from flavobacterium heparinum, collagen assays, collagen antibodies, and diamine oxidase liquid. The company was founded by Robert A. Heft on April 10, 1972 and is headquartered in Montréal, Canada. | Health Technology |
| Industrial Biotechnology Association of Canada | |
| Canadian Genetic Disease Network | |
Biocapital Investments Ltd
 Biocapital Investments Ltd Investment Banks/BrokersFinance Biocapital Investments Ltd is a company based in Montréal, Canada. | Finance |
Sectoral Asset Management, Inc.
 Sectoral Asset Management, Inc. Investment ManagersFinance Sectoral Asset Management, Inc. (Sectoral) is an investment management firm headquartered in Montréal, Canada. The firm was founded in 2000 by Jérôme G. Pfund and Michael J. Sjöström. They are a wholly-owned subsidiary of Sectoral Asset Management Holding Ltd. in Hong Kong. Sectoral manages public and private equity healthcare strategies for investors around the world. Their clients include sovereign wealth funds, private banks, and family offices. In addition, they have long-standing sub-advisory relationships with institutional investors in Europe and Asia. | Finance |
Clementia Pharmaceuticals, Inc.
 Clementia Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Clementia Pharmaceuticals, Inc. provides healthcare services. It is a biopharmaceutical company, which focuses on exploiting the science of novel retinoic acid receptor gamma agonists to address bone disease and involves in development and commercialization of treatments for people living with rare diseases. Clementia Pharmaceuticals was founded by Clarissa Desjardins and Jean-Claude Tardif on November 5, 2010 and is headquartered in Montreal, Canada. | Health Technology |
Ra Pharmaceuticals, Inc.
 Ra Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Ra Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the discovery and development of peptide-based drugs. It uses Extreme Diversity platform that allows to produce synthetic macrocyclic peptides. The company was founded by James W. Broderick and Douglas A. Treco on June 27, 2008 and is headquartered in Cambridge, MA. | Health Technology |
VisionGate, Inc.
 VisionGate, Inc. Medical SpecialtiesHealth Technology VisionGate, Inc. provides in-vitro automated 3D cell structure and analysis solutions. It focuses on early detection and prevention of lung cancer. The firm’s attendees include surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses and allied health professionals and patients. The company was founded by Alan C. Nelson and is headquartered in Phoenix, AZ. | Health Technology |
Lumos Pharma Sub, Inc.
Lumos Pharma Sub, Inc. Medical/Nursing ServicesHealth Services Lumos Pharma Sub, Inc. develops and commercializes a novel treatment for the rare disease creatine transporter deficiency. It focuses on bringing novel therapies to patients afflicted with unmet medical needs in severe, rare, and genetic diseases. The firm's technology LUM-001 is a repurposed small molecule that is a kinetically similar analog of creatine and has shown promising therapeutic potential for the treatment of creatine transporter deficiency. Lumos Pharma was founded by Richard J. Hawkins in 2010 and is headquartered in Austin, TX. | Health Services |
Eloxx Pharmaceuticals Ltd.
 Eloxx Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Eloxx Pharmaceuticals Ltd. provides biopharmaceutical research and development services. The firm specializes in the discovery, development, and commercialization of drug compounds for the treatment of genetic diseases. It focuses on the treatment of diseases caused by nonsense mutations, including Cystic fibrosis, Duchene Muscular Dystrophy, Usher syndrome, Ataxia-telangiectasia, Beta thalassemia, and Tay-Sachs Hurler syndrome. Its focus areas encompass clinical drug development and target drugs discovery programs. The company was founded by Silvia Noiman and Shmuel Tuvia in 2013 and is headquartered in Herzliya, Israel. | Health Technology |
Zingenix Ltd.
Zingenix Ltd. BiotechnologyHealth Technology Zingenix Ltd. provides gene therapy for orphan disorders. The private company is based in Tel Aviv, Israel. | Health Technology |
Parvus Therapeutics, Inc.
Parvus Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Parvus Therapeutics, Inc. manufactures and sells biopharmaceutical products. The private company is based in Calgary, Canada. | Health Technology |
